Management of Metastatic Dermatofibrosarcoma Protuberans

Introduction to Metastatic Disease

• The National Comprehensive Cancer Network recommends that stage 4 (metastatic) dermatofibrosarcoma protuberans carries a grave prognosis with 14.7% mortality risk, and imatinib mesylate 800 mg daily is the standard systemic therapy, achieving response rates of 62% in metastatic disease, with surgical resection of responding metastases considered in highly selected cases 1, 2

Understanding the Prognosis

• The prognosis of metastatic DFSP depends critically on histologic subtype, with fibrosarcomatous DFSP (FS-DFSP) having a metastatic risk of 10-23.5% and disease-specific mortality of 14.7%, nearly 20-fold higher than classic DFSP, according to the National Comprehensive Cancer Network 1, 2
• Local recurrence rate is 29.8% compared to 13.7% in classic DFSP, as reported by the National Comprehensive Cancer Network 1

Standard Treatment Approach

• The National Comprehensive Cancer Network and the European Society for Medical Oncology recommend imatinib as the standard medical therapy for metastatic DFSP not amenable to surgery, with a standard dose of 800 mg daily (400 mg twice daily) 3, 4, 5
• The expected outcomes in metastatic disease include an overall response rate of 62%, with 37% achieving complete response, and a median duration of response of 6.2 months, as reported by the Annals of Oncology 3

Role of Surgery in Metastatic Disease

• Surgical resection of metastatic disease should be considered in highly selected cases after imatinib response, with selection criteria including complete resectability of all visible lesions, response to chemotherapy/imatinib, and multidisciplinary evaluation, as recommended by the Annals of Oncology 3

Critical Management Considerations

• Referral to a specialized sarcoma center is mandatory for all patients with metastatic disease or FS-DFSP, with multidisciplinary consultation required when fibrosarcomatous transformation is identified, as recommended by the National Comprehensive Cancer Network 1, 2, 6
• Surveillance for metastatic disease includes CT imaging of draining nodal basin and chest recommended for FS-DFSP, with more aggressive surveillance warranted given 14.4% metastatic risk in FS-DFSP, as recommended by the National Comprehensive Cancer Network 1, 2